Amanote Research
Register
Sign In
A Cost Utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing Versus Standard Dosing of Risperidone for Treatment of Schizophrenia
Value in Health
- United Kingdom
doi 10.1016/j.jval.2014.03.1271
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
May 1, 2014
Authors
T. Yep
B. Devine
Publisher
Elsevier BV
Related search
Risperidone Versus Placebo for Schizophrenia
Cochrane Database of Systematic Reviews
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults With Schizophrenia
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
Economic Evaluation of a Pharmacogenetic Dosing Algorithm for Coumarin Anticoagulants in the Netherlands
Pharmacogenomics
Molecular Medicine
Genetics
Pharmacology
A Cost-Utility Analysis of Amisulpride and Paliperidone in the Treatment of Schizophrenia
Heliyon
Multidisciplinary
CYP2C9*8is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing
Pharmacogenomics
Molecular Medicine
Genetics
Pharmacology
Single Versus Multiple Daily Dosing of Lithium
Journal of Clinical Psychiatry
Medicine
Psychiatry
Mental Health
Pharmacogenetics-Guided Dosing for Fluoropyrimidines in Cancer Chemotherapy
Advances in Pharmacoepidemiology & Drug Safety
Genotype-Guided Versus Traditional Clinical Dosing of Warfarin in Patients of Asian Ancestry: A Randomized Controlled Trial
BMC Medicine
Medicine
Pmh42 - Cost-Utility Analysis of Cariprazine Compared to Risperidone Among Patients With Negative Symptoms of Schizophrenia in Selected Nordic Countries
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
